본문으로 건너뛰기
← 뒤로

The Impact and Evaluation of Immune Checkpoint Inhibitors on Clinical Survival in Patients with Advanced Osteosarcoma: A Systematic Review and Meta-Analysis.

메타분석 1/5 보강
Cancer investigation 📖 저널 OA 8.6% 2023: 0/2 OA 2024: 0/3 OA 2025: 0/12 OA 2026: 5/39 OA 2023~2026 2026 Vol.44(3) p. 350-362
Retraction 확인
출처

Li Y, Li Z, Cai L

📝 환자 설명용 한 줄

Osteosarcoma is an aggressive bone cancer primarily affecting children and adolescents, with low survival rates in advanced stages.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 systematic review

이 논문을 인용하기

↓ .bib ↓ .ris
APA Li Y, Li Z, Cai L (2026). The Impact and Evaluation of Immune Checkpoint Inhibitors on Clinical Survival in Patients with Advanced Osteosarcoma: A Systematic Review and Meta-Analysis.. Cancer investigation, 44(3), 350-362. https://doi.org/10.1080/07357907.2025.2599376
MLA Li Y, et al.. "The Impact and Evaluation of Immune Checkpoint Inhibitors on Clinical Survival in Patients with Advanced Osteosarcoma: A Systematic Review and Meta-Analysis.." Cancer investigation, vol. 44, no. 3, 2026, pp. 350-362.
PMID 41451786 ↗

Abstract

Osteosarcoma is an aggressive bone cancer primarily affecting children and adolescents, with low survival rates in advanced stages. A systematic review and meta-analysis were conducted following PRISMA guidelines to evaluate the impact of ICIs on survival and toxicity in advanced osteosarcoma. ICIs show potential in treating advanced osteosarcoma but are associated with significant toxicity and uncertain survival benefits. Further research is needed to define their role and identify biomarkers for predicting response. Close monitoring for adverse events is essential.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반